Trial Profile
A randomised, prospective study comparing the efficacy and safety of Simeprevir in combination with Peginterferon alpha2a+ Ribavirin and Peginterferon alpha2b+Ribavirin in patients with Hepatitis C virus genotype 1b infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2017
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Feb 2017 New trial record